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Measles re-emerged in a nationwide outbreak in 
Bulgaria from 2009 to 2011 despite reported high vac-
cination coverage at national level. This followed an 
eight-year period since the last indigenous cases of 
measles were detected. The Bulgarian National Centre 
of Infectious and Parasitic Diseases collated measles 
surveillance data for 2009–2011. We analysed data 
for age group, sex, ethnicity, diagnosis confirmation, 
vaccination, hospitalisation, disease complications, 
and death and describe the outbreak control measures 
taken. The outbreak started in April 2009 following 
an importation of measles virus and affected 24,364 
persons, predominantly Roma. Most cases (73%) were 
among children < 15 years old. Vaccination status was 
available for 52% (n  =  12,630) of cases. Of children 
1–14 years old, 22% (n  =  1,769) were unvaccinated 
and 70% (n = 5,518) had received one dose of a mea-
sles-containing vaccine. Twenty-four measles-related 
deaths were reported. The Roma ethnic group was 
particularly susceptible to measles. The magnitude of 
the outbreak resulted primarily from the accumulation 
of susceptible children over time. This outbreak serves 
as a reminder that both high vaccination coverage and 
closing of immunity gaps across all sections of the 
population are crucial to reach the goal of measles 
elimination.
Introduction
One of the largest outbreaks of measles in the World 
Health Organization (WHO) European Region in recent 
years occurred in Bulgaria from 2009 to 2011 and 
mostly affected Roma communities. The outbreak was 
first detected in spring 2009 after an eight-year period 
since the last indigenous measles cases were reported 
in 2001 [1]. The last major outbreak in Bulgaria occurred 
in 1991–1992 affecting over 20,000 persons [2].
By December 2009, two preliminary reports on the out-
break were published in the scientific literature [3,4]. 
Here we provide an overview of the measles outbreak 
in Bulgaria by analysing measles surveillance data 
for the whole outbreak period of 2009–2011. We also 
describe the control measures taken and discuss les-
sons learnt in relation to the WHO European Regional 
goal of eliminating measles by 2015 [5].
The measles vaccine was introduced in Bulgaria in 1969 
as a monovalent preparation [6]. A two-dose schedule 
began in 1983. The combined measles-mumps-rubella 
(MMR) vaccine has been given as the first dose at 13 
months of age since 1993, and as the second dose at 12 
years of age since 2001. For 2003–2008, the estimated 
national vaccine administrative coverage with the first 
MMR vaccine dose ranged from 94.7% to 96.2%, and 
for the second dose, from 89.4% to 94.3% [7].
Bulgaria forms part of the Balkan Peninsula in south-
eastern Europe and consists of 28 administrative 
regions. The latest census carried out in 2011 reported 
a population of 7,364,570, consisting of three main 
ethnic groups: Bulgarians (84.8%), Turks (8.8%) and 
Roma (4.9%). According to these official statistics, 
the Roma ethnic group numbers 325,343 persons dis-
tributed in all regions, but mainly in Montana (12.7% 




The surveillance of measles in Bulgaria relies on pas-
sively reported cases. Measles has been a statu-
tory notifiable disease since 1921 [9], and medical 
practitioners and medical laboratories are obliged to 
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immediately report suspected measles cases to the 
respective Regional Health Inspectorate (RHI) [10]. The 
RHIs are responsible for the epidemiological investiga-
tion of cases, tracing contacts of cases, undertaking 
control measures in affected families and communities 
and following up cases to register disease outcome. 
In 2005, the European Union case definition and case 
classification were adopted for reporting measles sur-
veillance data [11].
During the outbreak period 2009–2011, case-based 
data were submitted by all 28 RHIs to the Department of 
Epidemiology and Communicable Disease Surveillance 
of the National Centre of Infectious and Parasitic 
Diseases (NCIPD) in Sofia. In October 2009, a web-
based system for direct case-based data entry by the 
RHIs was implemented, gradually replacing previous 
manual methods of data collection and submission.
Case-based reports provided data for disease onset 
dates, date of birth, sex, diagnosis confirmation (i.e. 
laboratory-confirmed, epidemiologically linked and 
clinically compatible cases), vaccination, hospitalisa-
tion, complications and death. Information on vaccina-
tion status was obtained from patient immunisation 
cards whenever such cards were available. The inves-
tigators of the outbreak estimated the number of cases 
in Roma in parallel to routine data collection. We ana-
lysed surveillance data of cases with disease onset 
from 2009 until 2011 and separated the data by speci-
fied age groups.
Laboratory data
Laboratory confirmation of cases was carried out by 
detecting measles IgM antibodies in serum samples 
submitted mainly to the National Reference Laboratory 
of the NCIPD and, to a lesser extent, to the laboratories 
of three regional military hospitals. Clinical specimens 
of 20 laboratory-confirmed cases were submitted to 
the WHO European Regional Reference Laboratory for 
Measles and Rubella at the Robert Koch Institute in 
Berlin, Germany to determine the genotype of the mea-
sles virus (MV) circulating during the outbreak and to 
identify the likely origin of the virus. The specimens 
were taken from case-patients in different regions at 
various points in time (April 2009, May 2009, January 
2010, June 2010 and January 2011). Serum was sent 
for confirmatory testing, and urine specimens and 
throat swabs were submitted for virus detection, 
sequencing and genotyping of the MV RNA following 
standard instructions [12]. IgM and IgG serology tests 
were carried out as described by Tischer et al. [13] 
and genotyping was performed according to the WHO 
recommendation [14]. Sequences were aligned using 
ClustalW [15] and further analysed using SeqScape 2.5 
and MEGA 4.0 DNA analysis software [16]. Phylogenetic 
trees were constructed using the neighbour-joining 
method. Genotype assignment was performed by 
Figure 1



























































































Incidence of measles cases by region in Bulgaria, 2009–2011



































































































































































































Country incidence per 100,000 inhabitants is indicated in parentheses for each year.
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phylogenetic comparison with the MV reference strains 
as designated by WHO [17]. The obtained sequence 
data, genotype information and the official WHO MV 
sequence name and relevant epidemiologic data were 
submitted to the WHO database, Measles Nucleotide 
Surveillance (MeaNS) database [18] and GenBank.
Incidence and case-fatality calculations
Incidence was calculated with the number of measles 
cases as the numerator and the country and region 
population, obtained from the National Statistical 
Institute, as the denominator [19]. Unless other-
wise specified, we expressed incidence per 100,000 
inhabitants per year, and cumulatively for the three-
year period 2009–2011. Case-fatality ratio (CFR) was 
expressed as the number of measles-related deaths 
per 100 cases for the three-year period 2009–2011.
Ethical approval or informed consent was not consid-
ered to be necessary for this analysis since the data 
were collated under the Ministry of Health’s Regulation 
21 on epidemiological surveillance and control of com-
municable diseases in Bulgaria [10].
Results
Overall, 24,364 cases of measles were recorded 
between April 2009 and December 2011 corresponding 
to a cumulative incidence of 326 per 100,000 inhabit-
ants over the three-year period. The outbreak reached 
its peak by March 2010 (monthly incidence: 73 per 
100,000 inhabitants) when all 28 regions of Bulgaria 
were affected (Figure 1). Figure 2 shows the incidence 
of measles by region and by year, 2009–2011. During 
the three-year period of the outbreak, the highest 
incidence (> 500 cases/100,000 inhabitants) was reg-
istered in the regions of Sliven (838.8/100,000 inhab-
itants), Montana (716.7), Yambol (689.5), Haskovo 
(681.8), Pazardjik (556.1) and the Sofia region (523.0).
Of the total, 3,958 cases (16%) were laboratory-con-
firmed by detecting measles IgM antibodies in serum 
samples, 8,233 (34%) cases were epidemiologically 
linked to a laboratory-confirmed case and 12,173 (50%) 
cases were classified as clinically compatible cases.
Of the total, 12,472 (51%) were males. The median age 
of the cases was seven years (range: one day to 71 
years). Infants had the highest age-specific incidence 
per 100,000 inhabitants of 5,457 followed by 2,008 in 
children aged one to four years. Table 1 shows the age 
distribution of cases. Data on vaccination status were 
available for 52% (n = 12,630) of all reported cases 
(Table 2). Of the cases vaccinated with one MMR vac-
cine dose (n = 6,167; 49%), 11% (n = 656) were vacci-
nated within 14 days before onset of disease.
Of the total, 21,821 (89.6%) cases were estimated to 
occur among Roma. Indeed, the outbreak was first 
detected in April 2009 among the Roma community 
in the north-eastern part of the country involving the 
regions of Razgrad, Shumen, Silistra and Dobrich. The 
index case was identified as member of the Roma com-
munity aged between 20 and 30 years, who fell ill in 
March 2009, a few days after returning home from 
Hamburg, Germany. Initial symptoms included high 
fever, cough, coryza and malaise followed by the devel-
opment of a rash three days later. The clinical suspi-
cion of measles was confirmed by serological tests. 
Three of the index case’s family members subsequently 
acquired laboratory-confirmed measles. At the outset, 
the detection of further cases was delayed.
Mortality, hospitalisation and complications
Measles-related deaths were recorded in 24 patients 
(14 laboratory-confirmed, five epidemiologically 
linked, and five clinical cases), corresponding to a CFR 
of 0.1 per 100 measles cases. The deaths occurred as 
a consequence of severe complications of measles: 19 
cases (79%) suffered acute pneumonia and five cases 
(21%) suffered acute encephalitis. The median age at 
death was 1.71 years (range: 32 days–54 years). Infants 
and cases aged ≥ 25 years had a higher CFR (0.28% and 
0.2%, respectively) compared with cases aged 1–24 
years (0–0.09%). All deaths, with the exception of two 
cases of Bulgarian ethnicity aged between 40 and 49 
years of age, occurred in Roma.
Data on hospitalisation status were available for 92% 
(n = 22,296) of cases, of whom 86% (19,167) were hos-
pitalised. Among those hospitalised, 88% (16,854) 
were aged < 19 years. Information on measles-related 
complications was reported in 86% (21,039) of cases, 
of whom 38% (8,074) reported complications (Table 3).
Figure 3
Phylogenetic relationship between the World Health 
Organization reference strain of measles virus genotype 
D4 (MVs/Montreal.CAN/89-Ref-[D4]) and MV strains 



















Measles virus (MV) strains detected in Bulgaria are shown in bold. 
The World Health Organization-named strains of MV genotype 
D4 (MVs/Enfield.GBR/14.07, MVs/Manchester.GBR/10.09 and 
MVs/Hamburg.DEU/03.09) circulating in Europe in the same 
period are also included. The unrooted tree is based on the 456 
nt sequence encoding the C-terminus of the MV N gene. The 




All three nucleotide (nt) sequences of the variable 
part of MV N-gene (456 nt) derived from the three 
household contacts of the index case (MVs/Shumen.
BGR/15.09/1–3 [D4]) were identical to D4-Hamburg 
(MVs/Hamburg.DEU/03.09). D4-Hamburg showed a 
sequence deviation of one nt from D4-Enfield (MVs/
Enfield.GBR/14.07/[D4]), which was endemic in the 
United Kingdom between 2007 and 2009 [20,21].
The sequences derived from samples collected from 
four further cases later in 2009 are represented by 
MVs/Silistra.BGR/21.09/1–4 [D4]. In 2010, specimens 
from different parts of the country were collected and 
evaluated: from south-western (MVs/Blagoevgrad.
BGR/02.10/1 [D4], central (MVs/Plovdiv.BGR/03.10/1–6 
[D4] and northern Bulgaria (MVs/VelikoTarnovo.
BGR/10.11/1-2 [D4]). Nineteen out of the 20 laboratory-
confirmed cases that submitted clinical specimens for 
further laboratory analysis showed the sequence vari-
ant D4-Hamburg (Figure 3). MVs/Plovdiv.BGR/23.10/6 
[D4] was characterised by a sequence deviation of one 
nt, probably as a result of mutation.
Outbreak control measures
Outbreak management
The local health authorities implemented several 
control measures in line with the Bulgarian National 
Programme for the Elimination of Measles and 
Congenital Rubella Infection (2005–2010) [22]. The 
same month the outbreak was detected persons of 
Roma ethnicity living in the first-affected north-eastern 
regions of the country aged between 13 months and 30 
years were targeted for immunisation with one dose 
of MMR vaccine. In February 2010, the campaign was 
extended to a national level targeting persons aged 13 
months to 20 years who had not received two MMR vac-
cine doses. From the end of March 2010, the vaccine was 
available on request to all persons aged 30 years and 
older who had not received two MMR vaccine doses. 
Throughout the outbreak period, healthcare workers 
were offered a dose of MMR vaccine, irrespective of 
their immunisation status or age. Between April 2009 
and December 2010, 188,700 MMR vaccine doses were 
administered free of charge by the Ministry of Health 
(MoH) through routine immunisation services.
Special outreach teams composed of local epidemi-
ologists and health inspectors in collaboration with 
Roma health mediators (RHM) were deployed to vac-
cinate Roma communities. RHM are usually young 
adult members of the Roma community who are spe-
cially educated in the health field and trained to liaise 
between the community and healthcare facilities [23]. 
RHM assisted vaccination teams by improving commu-
nication between the team members, and leaders and 
members of the Roma community; by informing Roma 
leaders and parents of the benefits of vaccinations and 
by facilitating the transport of children to immunisation 
centres.
The MoH recommended that patients with measles 
living in crowded households be admitted to hospi-
tal to ensure better conditions for treatment and care 
and to minimise the spread of the disease in the poor 
neighbourhoods.
Outbreak communication
Activities to increase awareness of the outbreak among 
the public and healthcare professionals were under-
taken. When the outbreak started spreading beyond 
the north-eastern part of Bulgaria, the MoH issued a 
press release on the emerging outbreak, and provided 
information on the surveillance and immunisation 
activities. The MoH website also provided regularly 
updated information. Information leaflets were also 
distributed to the general population, and specifically 
to Roma, via their religious and community leaders. 
Information packages including a description of mea-
sles, updates on the status of the outbreak and a call 
to the public to be vaccinated were also regularly sup-
plied to the media.
The MoH distributed official circular letters to medical 
professionals in April 2009, August 2009 and February 
2010. Medical professionals were requested to pay 
special attention to patients presenting with rash and 
fever, to reach out to parents to explain the benefits of 
vaccination, and to ensure timely routine MMR vaccina-
tion of children.
Additional measures
The MoH regularly informed the WHO Regional Office 
for Europe and the European Centre for Disease 
Prevention and Control (ECDC) on the outbreak situ-
ation and measures taken to mitigate it. In February 
2010, experts from both organisations worked closely 
with the Bulgarian public health authorities to assess 
the outbreak and potential risk for further spread 
beyond the country, to review the current vaccination 
strategies and MMR vaccine supplies in the country for 
efficient control measures and to provide guidance on 
long-term strategies that address vaccination among 
Table 1
Age distribution of measles cases (n = 24,364) and 
measles-related deaths (n = 24), Bulgaria, 2009–2011
 
Age group (years)
No. of cases 
(n = 24,364) 






< 1 3,891 (16) 11 0.28
1–4 5,858 (24) 5 0.09
5–9 3,473 (14) 2 0.06
10–14 4,706 (19) 1 0.02
15–19 3,167 (13) 1 0.03
20–24 1,246 (5) 0 0
≥ 25 2,023 (8) 4 0.20
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vulnerable populations. Timely communication through 
these organisations alerted other countries to respond 
to any imported cases. In spring 2010, Bulgaria used 
the opportunity of the 2010 European Immunisation 
Week to advocate for and gain high-level political com-
mitment to immunisation.
Discussion
Our assessment of the outbreak relied on data col-
lected though routine surveillance based on passively 
reported cases. Such systems are notorious for under-
reporting and incompleteness of data. On the other 
hand, some over-estimation of cases may have occurred 
since half of these were not confirmed by laboratory 
testing or were epidemiologically linked, and patients 
with other rash- and fever-like illnesses may have been 
wrongly reported as measles cases. Furthermore, since 
there are no provisions for data collection by ethnic-
ity, the investigators could only estimate the number 
of Roma cases based on their observations. Moreover, 
our analysis on vaccination status was limited to the 
48% of cases with data on this variable. Despite these 
limitations, the data we present strongly indicate that 
the Roma ethnic group was particularly susceptible 
to measles. Measles outbreaks have also emerged in 
Roma communities in other European countries [24-
27]. As in Bulgaria, their vulnerability was brought to 
light when the MV was imported from abroad.
Similar to the measles outbreak in neighbouring 
Greece in 2005–2006 [25], sub-optimal immunisation 
coverage among Roma children largely contributed to 
this outbreak. A cross-sectional survey of coverage 
with routine immunisations in children born in 2006 in 
the region of Sofia showed that out of 324 Roma chil-
dren eligible for immunisation, only 68.8% (n = 223) 
received the first MMR vaccine dose [28].
According to a seroprevalence survey that included 
1,666 individual samples collected in 2001–2004, 
Bulgaria was one of several European countries that 
had not met the WHO targets for measles susceptibility 
[29]. For the 2–4 and 5–9 year-old age groups, 30.4% 
and 25.9% respectively, were seronegative for measles. 
The WHO susceptibility targets for these consecutive 
age groups are < 15% and < 10% [30]. A seroprevalence 
survey on 249 hospitalised non-measles patients 
aged ≤ 65 years conducted in 2008 by NCIPD in Burgas, 
Bulgaria, revealed that 51 patients (20.5% (95% CI 
15.6–27.0%)) were measles IgG-negative [31]. These 
results suggest that the population susceptibility to 
measles at national level is probably higher than that 
indicated by the reported minimum of 94.7% immuni-
sation coverage for the first dose of routine measles 
vaccination for 2003–2008 [7]. In Bulgaria, immuni-
sation coverage is estimated using the administrative 
method as a proportion of the number of routinely 
administered vaccine doses by eligible birth cohorts of 
the previous year. An overestimation of the coverage 
may have resulted if the denominator did not include 
all the population targeted for vaccination. Lack of 
registration of Roma children with a healthcare facility 
has, indeed, been documented [32].
The magnitude of the outbreak underlined the sub-
stantial number of susceptible children that had accu-
mulated gradually since the last major nationwide 
outbreak in 1991–1992. During the health reforms of 
the 1990s there were a number of challenges in ensur-
ing access to quality child health services, including 
immunisation, to the Roma minority [33]. In addition, 
since primary vaccine failure is reported to occur in 
2–5% of vaccinated children after the first measles-
containing vaccine (MCV) dose given at 12 months of 
age [34], the accumulation of non-responders to the 
first MCV dose probably also contributed to the pool 
of susceptible individuals. This also explains, at least 
in part, the relatively large proportion (49%, n = 6,167) 
of cases reported having received one MCV dose, since 
in Bulgaria, the second dose is not given until 12 years 
of age. Other potential contributing factors may include 
incorrect documentation on vaccination status and 
issues with the cold chain. Nonetheless, 11% (n = 656) 
of these cases developed measles within 14 days of 
vaccination, which was probably administered as part 
of the outbreak control measures while they were in 
the incubation period following infection with MV.
Roma communities are often separated from the main-
stream of social and economic life in segregated, 
often crowded, neighbourhoods; however, there is 
intensive contact between the different communities. 
Table 2
Measles cases with known vaccination status, Bulgaria, 2009–2011 (n = 12,630)
 















19 0.6% 2,085 58.7% 1,660 81.6% 1,773 76.2% 541 45.9% 89 36.3% 6,167 48.8%a
Vaccinated 
with at least 
two doses
3 0.1% 107 3.0% 151 7.4% 366 15.7% 518 43.9% 93 38.0% 1,238 9.8%
a Of the cases vaccinated with one MMR vaccine dose (n = 6,167), 11% (n = 656) were vaccinated within 14 days before onset of measles.
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This explains the widespread transmission across the 
country, and also beyond its borders. Between 2009 
and 2011, MV variant D4-Hamburg appeared in several 
European countries. The spread of the MV was mostly, 
but not exclusively, associated with travelling mem-
bers of the Roma ethnic group [35].
Poor maternal education was shown to be a risk factor 
for the development of measles-related complications 
[36]. However, the high proportion of hospitalised 
cases reflects the MoH’s recommendation to hospital-
ise measles patients living in poor conditions. While 
this measure may have benefitted patients admitted 
to hospital, its impact in limiting the spread of dis-
ease in the Roma community is difficult to estimate. 
Inadvertently, it probably intensified nosocomial trans-
mission [37]. During this outbreak, MV transmission 
occurred in several healthcare settings and health-
care workers emerged as a group at risk of acquiring 
measles. This necessitates clear recommendations to 
adhere to infection control measures in healthcare set-
tings and to ensure healthcare workers are adequately 
protected.
The Bulgarian health authorities implemented the 
necessary control measures with coordination, sup-
port and directives from the MoH. Regular communica-
tion with the WHO Regional Office for Europe and the 
ECDC allowed transparency, dialogue and advice to be 
sought. The large number of reported cases posed a 
major challenge to the surveillance system that relied 
on time-consuming manual methods of data collection 
and submission. With the support of the WHO Regional 
Office for Europe these methods of data collection 
were replaced by a web-based system allowing direct 
and timely case-based data entry by the RHIs.
The RHIs played a key role in executing control meas-
ures despite financial and human resource limitations. 
Supplementary immunisation activities were instigated 
to first target Roma in the affected regions and later 
the general population. Concurrently, healthcare pro-
fessionals were urged to strengthen routine immunisa-
tion services. Despite these efforts, the initial control 
measures were arguably not implemented rapidly and 
widely enough to curb the outbreak. The clinicians’ 
unfamiliarity with the disease probably contributed to 
the delay in detecting cases and subsequent response 
to the first cases. Nevertheless, resources permitting, 
a nationwide vaccination campaign targeting all infants 
aged nine months and older, children and young adults 
would probably have curtailed the outbreak sooner.
The outbreak in Bulgaria has served to further develop 
national and local programmes in collaboration with 
Roma organisations with the aim of integrating better 
the Roma community into the health system. Bulgaria 
was one of the first countries in the WHO European 
Region to launch the Guide to Tailoring Immunisation 
Programmes that resulted in several efforts to be 
undertaken, such as improving curricula and training of 
RHM across the country [38-40]. In addition, Bulgaria 
participated in a European collaborative project, Let’s 
Talk About Protection, which aims to communicate 
effectively and address patients’ concerns on vaccine 
topics [41]. This has resulted in the publication of a 
practical guide to vaccination adapted to the context in 
Bulgaria, and intended for use by healthcare workers 
and visual aid material in the form of handy flip charts 
for general practitioners and RHM [42].
The outbreak serves as another reminder to all coun-
tries of the WHO European Region of their commit-
ment to eliminate measles [43]. To reach this goal 
every country needs to ensure that their immunisation 
programmes achieve and maintain high vaccination 
coverage (≥ 95%) with two MCV doses, while also iden-
tifying and closing immunity gaps across all population 
segments.
In conclusion, a nationwide outbreak of measles in 
Bulgaria during 2009–2011 resulted from the accu-
mulation of a large susceptible population despite 
reported high measles vaccination coverage at national 
level. The outbreak particularly highlighted the vulner-
ability of Roma communities in Bulgaria to measles. In 
addition to low coverage among Roma, accumulation 
of non-responders to the first MCV dose could have 
also contributed to the pool of susceptible individuals. 
The development and implementation of strategies to 
identify susceptible individuals and close immunity 
gaps across all segments of the population are of vital 
importance in relation to reach the measles elimination 
goal.
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